fbpx
QQQ
+ 2.58
328.93
+ 0.78%
DIA
+ 2.29
343.25
+ 0.66%
SPY
+ 2.93
416.17
+ 0.7%
TLT
-0.69
140.61
-0.49%
GLD
+ 1.55
168.49
+ 0.91%

Digital Therapeutics Field Is Fast On The Rise, Ehave Is Advancing Research In Psychedelics And ADHD Therapy

June 30, 2020 9:27 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Digital Therapeutics Field Is Fast On The Rise, Ehave Is Advancing Research In Psychedelics And ADHD Therapy

The upcoming Benzinga Deal Room, set to take place on June 30, 2020, connects well-vetted cannabis companies with accredited investors looking to place capital. Among the line-up is Ehave.

Ehave, Inc. (OTC:EHVVF) is a provider of digital therapeutics, delivering evidence-based therapeutic interventions to patients. 

Ehave’s main focus is on helping improve the standard care in therapeutics to prevent/treat brain disorders or diseases through the use of digital therapeutics, psychedelics, and other therapies. An initial focus for Ehave has been on the remediation and assessment of attention deficit hyperactivity disorder (ADHD). 

The company’s main product, the Ehave Dashboard, empowers patients, healthcare providers, and payers to address a wide range of conditions through high quality, safe, and effective data-driven involvement with intelligent and accessible tools.  

CEO of Ehave, Benjamin Kaplan, will be presenting at Benzinga’s upcoming Deal Room. Kaplan will be discussing an opportunity with the company’s ADHD applications and its approach to the psychedelic sector.

He will also be providing an overview of Ehave’s plan to monetize and expand to achieve leadership status in the market.

“I feel very excited about the path Ehave is taking,” said Kaplan. “From the advancing of ADHD research and approvals in this sector to our opportunities arising from the Psychedelic explosion.” 

To learn more about Ehave and its opportunities, you can sign up for Benzinga’s Deal Room by clicking here.

Photo by Toa Heftiba on Unsplash


Related Articles

Psyched: MDMA On Health Canada's Radar, MindMed Seeks FDA Support For LSD, Numinus Buys Mindspace

Health Canada Considers MDMA And Psilocybin 'Special Access' Program This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).” read more

'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. read more

'Psyched': Mota Buys German Psilocybin Producer, Champignon Announces New CEO, $10M In Funding

Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. read more

2020 Was The Year of Psychedelics — Here's Why

While many 2020 memories will be gladly left behind, that's not necessarily the case for psychedelics. There was unprecedented renaissance as psychedelic compounds, and their potential to treat mental health conditions, became one of the centerpieces of this year’s public conversation.  read more